Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Abstract

IMPORTANCE:

High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis.

OBJECTIVE:

To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay.

DESIGN, SETTING, AND PATIENTS:

Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study.

EXPOSURE:

Treatment with interferon beta-1b, 250 μg, for at least 2 years.

MAIN OUTCOME MEASURES:

Levels of IL-17F at baseline and month 6 as well as the difference between the IL-17F levels at month 6 and baseline were compared between the following: (1) patients with less disease activity vs more disease activity; (2) patients with no disease activity vs some disease activity; and (3) responders vs nonresponders.

RESULTS:

Levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging criteria. Relapses and new lesions on magnetic resonance imaging were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change. All patients with levels of IL-17F greater than 200 pg/mL were associated with poor response with some clinical or radiological activity.

CONCLUSIONS AND RELEVANCE:

An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.

• Authors: Hans-Peter Hartung, Lawrence Steinman, Douglas S Goodin, Giancarlo Comi, Stuart Cook, Massimo Filippi, Paul O'Connor, Douglas R Jeffery, Ludwig Kappos, Robert Axtell, Volker Knappertz, Timon Bogumil, Susanne Schwenke, Ed Croze, Rupert Sandbrink, Christopher Pohl
• Journal: JAMA neurology (JAMA Neurol) Vol. 70 Issue 8 Pg. 1017-21 (Aug 2013) ISSN: 2168-6157 [Electronic] United States
• PMID: 23732754 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Interleukin-17
• Interferon beta-1b
• Interferon-beta

Topics

• Adult
• Disability Evaluation
• Disease Progression
• Female
• Humans
• Immunoassay (methods)
• Interferon beta-1b
• Interferon-beta (administration & dosage, physiology, therapeutic use)
• Interleukin-17 (biosynthesis, blood, physiology)
• Magnetic Resonance Imaging
• Male
• Multiple Sclerosis, Relapsing-Remitting (drug therapy, immunology, metabolism)
• Random Allocation
• Time Factors
• Treatment Outcome